illumina

Shares of Illumina, Inc. (NASDAQ: ILMN) hit a new 52-week high of $198.47 Wednesday and ended the day higher by nearly 15 percent after the company reported top- and bottom-line beats in its second-quarter earnings report. However, the results weren't good enough for analysts at Barclays who are...

Three leading biotech companies will step into the earnings spotlight this week. Consensus forecasts from Wall Street analysts call for earnings growth from just two of them. And only one of them has topped estimates by double-digits in recent quarters. While the biotechnology industry has had a...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of both of these stocks rose sharply during the two-week period. Short sellers shied away from many of the...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out as leaders of that trend in those two weeks. Shares of one of those two stocks rose while the other slumped during the period. Short sellers moved on only a few of the leading...

Short interest in many leading biotech stocks declined in the most recent period. Bucking that trend is a biotech company that soon will be acquired by an overseas peer. Short sellers retreated most sharply from a biotech that some analysts now see as a value stock. Between the March 31 and April...

Illumina, Inc. (NASDAQ: ILMN) announced after Thursday's market close that it has committed $100 million into a new venture capital firm. Illumina's new fund, named Illumina Ventures, was established by Nicholas Naclerio, the company's former senior vice president of corporate and venture...

Featured stories this weekend in Barron's ponder the prospects for a package delivery giant, a Dublin-based packaging company and a leading biotech company. Other featured articles include the annual ranking of the best online brokers. The cover story presents the annual list of the 30 best CEOs...

Pharmaceutical giants Merck & Co., Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE) are expected to post quarterly results this week. Analysts are looking for different top and bottom line results from each. A few other pharmaceutical and biotech companies are on deck this week as well. Two of...

Short interest changes in biotech stocks were mixed during the most recent period. Baxalta Inc (NYSE: BXLT) and Juno Therapeutics Inc (NASDAQ: JUNO) saw short interest surges in late September. Short interest in Medivation Inc (NASDAQ: MDVN) plunged during that time. With the ongoing market...

By and large, the number of shares short in the leading biotech and emerging pharmaceutical stocks shrank between the July 15 and July 31 settlement dates. The trend was particularly noticeable in Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Celgene Corporation (NASDAQ: CELG), which saw sharp...

Some of the biggest swings in short interest among the leading biotechs and emerging pharmaceuticals between the May 29 and June 15 settlement dates happened to Amgen, Inc. (NASDAQ: AMGN), Gilead Sciences, Inc. (NASDAQ: GILD) and Illumina, Inc. (NASDAQ: ILMN). Let's take a quick look at how these...

While short interest in most of the leading biotechs and emerging pharmaceuticals shrank between the April 15 and April 30 settlement dates, three stocks bucked that trend. Biogen Inc (NASDAQ: BIIB), Illumina, Inc. (NASDAQ: ILMN) and Juno Therapeutics Inc (NASDAQ: JUNO) saw the number of their...

By and large, the short interest moves in the leading biotechs and emerging pharmaceuticals were mild between the February 27 and March 13 settlement dates. However, Celgene Corporation (NASDAQ: CELG), Illumina, Inc. (NASDAQ: ILMN) and Medivation Inc (NASDAQ: MDVN) saw double-digit percentage...

Biotechs continue to prove volatile this year. While Gilead Sciences, Inc. (NASDAQ: GILD) and Illumina, Inc. (NASDAQ: ILMN) saw a sizable drops in short interest between the September 15 and September 30 settlement dates, short sellers loaded up on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX...

U.S. stocks were marginally lower, as investors and traders may be waiting on the sidelines for further clarity on geopolitical tension. Volume was lighter than usual, as the composite volume on the New York Stock Exchange was 2.2 billion right before the closing bell. Typically, 2.1 billion...